Summit Therapeutics Inc (NASDAQ:SMMT) shares, rose in value on Thursday, March 27, with the stock price up by 3.57% to the previous day’s close as strong demand from buyers drove the stock to $20.60.
Actively observing the price movement in the last trading, the stock closed the session at $19.89, falling within a range of $19.7 and $20.79. The value of beta (5-year monthly) was -1.042. Referring to stock’s 52-week performance, its high was $33.89, and the low was $2.10. On the whole, SMMT has fluctuated by 12.57% over the past month.
With the market capitalization of Summit Therapeutics Inc currently standing at about $15.20 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-23.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SMMT’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of SMMT currently trading nearly 5.02% and 0.94% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.71, while the 7-day volatility ratio is showing 6.38% which for the 30-day chart, stands at 7.42%. Furthermore, Summit Therapeutics Inc (SMMT)’s beta value is -0.50, and its average true range (ATR) is 1.44.
A comparison of Summit Therapeutics Inc (SMMT) with its peers suggests the former has fared considerably weaker in the market. SMMT showed an intraday change of 3.57% in last session, and over the past year, it grew by 528.05%%.
Data on historical trading for Summit Therapeutics Inc (NASDAQ:SMMT) indicates that the trading volumes over the past 10 days have averaged 2.11 and over the past 3 months, they’ve averaged 2.44 million. According to company’s latest data on outstanding shares, there are 737.63 million shares outstanding.
Nearly 84.39% of Summit Therapeutics Inc’s shares belong to company insiders and institutional investors own 12.61% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 21.22 million shares as on 2025-03-14, resulting in a short ratio of 7.34. According to the data, the short interest in Summit Therapeutics Inc (SMMT) stood at 1783.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 21.45 million. The stock has risen by 15.44% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SMMT stock heading into the next quarter.
